Increased Expression of Regeneration and Tolerance Factor in Individuals with Human Immunodeficiency Virus Infection

BRIAN K. DUChATEAU,1 GERALD W. LEE,1 MAXWELL P. WESTERMAN,2 AND KENNETH D. BEAMAN*1*

Clinical Immunology Laboratory and Department of Microbiology/Immunology, Finch University of Health Sciences/The Chicago Medical School, North Chicago, Illinois 60064,1 and Department of Medicine, Mount Sinai Hospital, Chicago, Illinois 606082

Received 27 March 1998/Returned for modification 13 May 1998/Accepted 9 December 1998

Regeneration and tolerance factor (RTF) plays a pivotal role in successful pregnancy outcome and has potent immunomodulating properties. During pregnancy, it is abundantly expressed in the placenta and on peripheral B lymphocytes. Several lines of evidence suggest that both successful pregnancy outcome and progression from human immunodeficiency virus (HIV) infection to AIDS are associated with a Th2-type response. As a result, we hypothesized that the cellular expression of RTF may also be increased during infection with HIV. Using flow cytometric analysis, we showed a significantly (P < 0.01) increased expression of RTF on CD3+ cells obtained from individuals with HIV over that for individuals without HIV. On average, 32.1% of the CD3+ cells from individuals with HIV expressed high levels of RTF. In contrast, an average of only 6.7% of the CD3+ cells from individuals without HIV expressed high levels of RTF. Similar results were obtained when CD19+ cells from individuals with (mean, 44.1%) and without (mean, 25.8%) HIV were evaluated. Linear regression analysis suggested that high levels of RTF expression by CD3+ cells correlated better with viral load (r value, 0.46) than with absolute CD4 count (r value, 0.09). While additional experiments are necessary to delineate the precise immunologic role of RTF, our current data suggest that RTF expression during HIV infection may be a useful marker of immune activation.

We showed an increase in RTF expression on peripheral blood CD3+ and CD19+ cells obtained from individuals infected with HIV over that for individuals not infected with HIV.

MATERIALS AND METHODS

Study subjects. HIV-infected individuals did not have to meet any special criteria to be included in the study. During a 12-week period, all available sodium-heparin-anticoagulated peripheral blood samples obtained from HIV-infected individuals at Mount Sinai Hospital, Chicago, Ill., were included in the study. During this time, 25 samples were collected from individuals aged 25.4 to 64.6 years (mean, 39.5 years). Of the 25 patients evaluated, 3 were inpatients and 22 were outpatients. Furthermore, all three AIDS surveillance case definitions (3) based on absolute numbers of CD4+ T lymphocytes were included in this study (category 1, >500 CD4+ T lymphocytes/μl of blood; category 2, 499 to 200 CD4+ T lymphocytes/μl of blood; and category 3, <200 CD4+ T lymphocytes/μl of blood). Sodium-heparin-anticoagulated peripheral blood samples were also obtained from 13 uninfected, healthy donors (aged 22.3 to 50.8 years; mean, 32.5 years) at Finch University of Health Sciences/The Chicago Medical School, North Chicago, Ill. The appropriate local institutional review boards approved this study.

Determination of absolute CD4 counts and acquisition of clinical information. The percentages of CD4+ and CD8+ T lymphocytes present in the lymphocyte population of samples obtained from HIV-infected individuals were determined by using flow cytometry and appropriately conjugated antibodies. The number of lymphocytes present in the samples was determined with an automated hematology machine. Absolute CD4 count was then calculated by multiplying the percentage of CD4+ T lymphocytes by the absolute lymphocyte count. Absolute CD4 counts are expressed as the number of cells per microliter of blood. Viral load determinations were obtained by a retrospective analysis of hospital-patient records.

Antibody reagents. Peripheral blood T and B lymphocytes were identified with phycoerythrin (PE)-conjugated antibodies to CD3 (Coulter, Miami, Fla.) and CD19 (Coulter). A combination of fluorescein isothiocyanate (FITC)-conjugated MAAb to CD45 and PE-conjugated MAAb to CD14 (Ortho Diagnostics, Raritan, N.J.) was also used. The murine hybridoma cell line 2C1 was used to generate anti-RTF MAAb. This hybridoma was generated with a synthetic peptide (Clontech, Palo Alto, Calif.) representing amino acids 488 to 514 of the RTF gene sequence (15) and produces a MAAb of the immunoglobulin G1 (IgG1) isotype (unpublished data). For ascerts production, hybridoma cell line 2C1 was grown in vitro and injected into the peritoneal cavities of pristane (Sigma, St.

* Corresponding author. Mailing address: FUHS/The Chicago Medical School, Clinical Immunology Laboratory, 3333 Green Bay Rd., North Chicago, IL 60064. Phone: (847) 578-3444. Fax: (847) 578-3349. E-mail: kbeaman@aol.com.
Louis, Mo.)-primed BALB/c mice (Charles River, Wilmington, Mass.). Ascites fluid containing anti-RTF MAb was collected 14 to 21 days after injection, purified, and conjugated by standard methods (11). Following conjugation, the FITC (495 nm)-to-protein (280 nm) ratios of the MAb solutions were determined spectrophotometrically to be 1.0 and 1.1. Protein concentrations were adjusted to 0.5 mg/ml. The specificity of the anti-RTF MAb was evaluated by using murine IgG2a (Ortho Diagnostics) and IgG1 (Becton Dickinson, San Jose, Calif.) isotype control antibodies conjugated with PE and FITC. The specificity of the anti-RTF MAb was further evaluated with unconjugated mouse IgG1 (PharMingen, San Diego, Calif.).

Analysis of peripheral blood samples by flow cytometry. Within 24 h after collection, peripheral blood samples from HIV-infected and uninfected individuals were prepared for flow cytometric analysis with the Coulter Clone Immuno-Lyse system. One-hundred-microliter samples of peripheral blood were labeled with 10 μl of antibody to either CD45/CD14, CD3, or CD19 or isotype control antibodies. Then, 30 μl of FITC-conjugated anti-RTF MAb was added to tubes containing antibody to CD3 and CD19. After labeling, samples were immediately analyzed with a Coulter Epics XL-MCL flow cytometer. Data from 10,000 cells were acquired and analyzed with histogram and dot plot profiles of PE and FITC fluorescence. Lymphocytes were identified with forward and side light scatter parameters. Conjugated antibodies to CD45/CD14 were used to validate the established lymphocyte gate. CD3 and CD19 cells were identified by PE fluorescence. A second gate was established around these cells, and RTF expression of CD3 and CD19 cells was determined by FITC fluorescence. Fluorescence negatives were defined with conjugated isotype control antibodies. Markers established with isotype control antibodies suggested that all individuals evaluated expressed RTF. To demonstrate differences in RTF expression between infected and uninfected individuals, all subsequent markers were established with samples obtained from uninfected individuals. Marker placement was established such that <12% of the CD3 T cells from >90% of all uninfected individuals evaluated expressed high levels of RTF. As a result, percentages indicate cells expressing high levels of RTF in individuals not infected and infected with HIV.

Statistical evaluation. Statistical analysis was conducted with the Statworks computer program. P values were determined by an unpaired t test. r values were determined by linear regression analysis. The alpha level was set at 0.05 before the experiments were started. The standard error of the mean was also calculated for each of the groups represented in Fig. 3 and 4.

RESULTS

Evaluation of anti-RTF MAb specificity. The specificity of the anti-RTF MAb was evaluated with two different isotype control antibodies. Neither IgG2a (Fig. 1A and D)- nor IgG1 (Fig. 1B and E)-conjugated isotype control antibodies bound to the surface of cells obtained from individuals without (Fig. 1A and B) or with (Fig. 1D and E) HIV infection. Furthermore, preincubation of peripheral blood samples with unconjugated mouse IgG1 (15 μg) did not decrease the amount of RTF expression detected in individuals with or without HIV infection (data not shown). Flow cytometric histograms also suggested that CD3+ T lymphocytes obtained from uninfected individuals expressed low levels of RTF (Fig. 1C). To demonstrate differences in RTF expression between infected and uninfected individuals, markers were established with samples obtained from uninfected individuals. As a result, percentages indicate cells expressing high levels of RTF in individuals not infected (Fig. 1C) and infected (Fig. 1F) with HIV.

Flow cytometric analysis of RTF expression on CD3+ and CD19+ cells. We used flow cytometric analysis to evaluate
RTF expression by peripheral blood CD3\(^+\) and CD19\(^+\) cells from individuals infected and not infected with HIV. Representative flow cytometric dot plots demonstrate the increased expression of RTF on CD3\(^+\) and CD19\(^+\) cells from an individual with (Fig. 2A and B) and without (Fig. 2C and D) HIV infection. When additional individuals were evaluated, we demonstrated a significantly \((P < 0.01)\) increased expression of RTF on CD3\(^+\) and CD19\(^+\) cells from individuals with HIV over that for uninfected individuals. On average, 32.1% of the CD3\(^+\) cells expressed high levels of RTF in individuals infected with HIV (Fig. 3). In contrast, an average of only 6.7% of the CD3\(^+\) cells expressed high levels of RTF in individuals not infected with HIV (Fig. 3). We further demonstrated that a significantly \((P < 0.03)\) greater percentage of CD19\(^+\) cells expressed high levels of RTF in individuals infected with HIV (mean, 44.1%) than in individuals not infected with HIV (mean, 25.8%) (Fig. 4).

**Relationship of RTF expression on CD3\(^+\) cells to other clinical parameters.** Absolute numbers of CD4\(^+\) T lymphocytes and the percentages of both CD4\(^+\) and CD8\(^+\) T lymphocytes were determined for each individual at the same time that RTF expression was evaluated (Table 1). Individuals representing all three AIDS surveillance case definitions (3) were included in the study. Linear regression analysis suggested that RTF expression by CD3\(^+\) cells did not correlate well with absolute CD4 count (Fig. 5A), as this comparison yielded an \(r\) value of 0.09. However, the five individuals with the greatest percentage of CD3\(^+\) cells expressing RTF did have absolute CD4 counts below 200 cells/\(\mu\)l of blood (Table 1, individuals 1 to 5). In addition, RTF expression on CD3\(^+\) cells did increase as absolute CD4 counts decreased. Viral load determinations were also obtained for a subset of HIV-infected individuals included in the study (Table 1). In most cases, viral load determinations were made at the same time that RTF expression was evaluated. Linear regression analysis yielded an \(r\) value of 0.46 when RTF expression by CD3\(^+\) cells was compared with viral load (Fig. 5B). Furthermore, RTF expression on CD3\(^+\) cells did increase as viral burden increased.

**DISCUSSION**

Human infection with HIV results in a multitude of complex immunologic changes that are often manifested by the modulation of different immune markers. In the current study, we demonstrated an increased cellular expression of RTF on CD3\(^+\) and CD19\(^+\) cells from individuals with HIV over that
for uninfected individuals. Specifically, a greater percentage of CD3\(^+\) cells expressed high levels of RTF in individuals infected with HIV (mean, 32.1%) than in individuals not infected with HIV (mean, 6.7%). Similar results were obtained when CD19\(^+\) cells from individuals infected (mean, 44.1%) and not infected (mean, 25.8%) with HIV were evaluated for high levels of RTF expression. Divergent T-lymphocyte expression of RTF in these different groups of individuals may be due to the skewing of different T-lymphocyte subpopulations. The CD3\(^+\) cell populations in HIV-infected and uninfected individuals are composed of very different T-lymphocyte subpopulations. However, in preliminary studies we found that individuals with HIV expressed high levels of RTF on both CD4\(^+\) and CD8\(^+\) T lymphocytes (data not shown). Further studies are needed to conclusively delineate which T-lymphocyte subsets express RTF.

It is also possible that divergent RTF expression may be reflective of individual risk group differences. The majority of HIV-infected individuals included in the study contracted disease by heterosexual means and belong to the same risk group as the uninfected control individuals. However, a subset of HIV-infected individuals included in the study contracted disease by intravenous drug use. This risk group is not reflective of the uninfected control group.

Linear regression analysis suggested that high levels of RTF expression by CD3\(^+\) cells correlated better with viral load (r value, 0.46) than with absolute CD4 count (r value, 0.09). These results may suggest that increased RTF expression is designative of an immunologic change(s) not indicated by an absolute CD4 count. These results may also indicate that the relationship between RTF expression and absolute CD4 count is nonlinear. That is, expression of RTF may not correlate with absolute CD4 count until the health of an individual is in an advanced deleterious state. In support, we showed that the five individuals with the greatest percentage of CD3\(^+\) cells expressing RTF all had absolute CD4 counts below 200 cells/\(\mu\)l of
RTF expression is coordinately upregulated during states of immune activation that exist during bacterial and viral infections. Infection with HIV is known to result in immune activation and the subsequent modulation of several different immune activation markers (21, 31). Cells from HIV-infected individuals do have an increased propensity to undergo apoptosis (21–23, 25). Our unpublished data suggest that RTF is coordinately expressed on the surface of apoptotic cells. Further studies are needed to determine if RTF expression changes with clinical status during both remission and progression of disease.

Our current findings also raise intriguing questions regarding the precise immunologic role of RTF expression during HIV infection. We have shown previously that RTF plays a pivotal role in successful pregnancy outcome (1, 8, 26). Successful pregnancy is known to be associated with a polarization from a Th1- to a Th2-type response (33). Similarly, the progression from infection with HIV to AIDS may also be driven by a shift from a Th1- to a Th2-type response (5–7, 19). The results of our current study demonstrate a very pronounced increase in the percentage of cells expressing high levels of RTF during infection with HIV. Collectively, the results of these studies suggest that expression of RTF may be coordinately upregulated during Th2-type responses. However, other possible immunologic roles for RTF expression during HIV infection exist. Direct infection of T lymphocytes with HIV cannot result in cell death by a variety of mechanisms (28). Apoptosis has been suggested as a mechanism of T-lymphocyte depletion (21, 31). Cells from HIV-infected individuals do have an increased propensity to undergo apoptosis (21–23, 25), particularly in individuals with progressed disease (22, 25). Our unpublished data suggest that RTF is coordinately expressed on the surface of apoptotic cells. Further studies are needed to determine if T lymphocytes expressing RTF during HIV infection are also apoptotic.

**ACKNOWLEDGMENTS**

We thank Sondra Allen at Mount Sinai Hospital, Chicago, Ill., for assistance with compiling patient information. We also thank Gail Hoppe and Catrina Crociani at The Chicago Medical School, North Chicago, Ill., for their clerical and technical assistance.
REFERENCES

1. Beaman, K. D., and R. C. Hoversland. 1988. Induction of abortion in mice with a monoclonal antibody specific for suppressor T-lymphocyte molecules. J. Reprod. Fertil. 82:691–696.

2. Beaman, K. D., V. Angkachatchai, and A. Gilman-Sachs. 1996. Tj6: the pregnancy-associated cytokine. Am. J. Reprod. Immunol. 35:338–341.

3. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection. Morbid. Mortal. Weekly Rep. 44:RR–17.

4. Chaouat, G., A. A. Meliani, J. Martal, R. Raghupathy, J. Elliot, T. Mosmann, and T. G. Wegmann. 1995. IL-10 prevents naturally occurring fetal loss in the CBA X DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-γ. J. Immunol. 154:4261–4268.

5. Clerici, M., and G. M. Shearer. 1993. A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 14:107–111.

6. Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15:575–581.

7. Clerici, M., T. A. Wynn, J. A. Berzofsky, S. P. Blatt, A. Sher, R. L. Coffman, and G. M. Shearer. 1994. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals with the human immunodeficiency virus. J. Clin. Invest. 95:768–775.

8. Coulam, C. B., and K. D. Beaman. 1995. Reciprocal alteration in circulating Tj6+ CD19+ and Tj6+ CD56+ leukocytes in early pregnancy predicts success or miscarriage. Am. J. Reprod. Immunol. 32:219–224.

9. Ginaldi, L., M. DeMartinis, A. D’Ostilio, A. DeGennaro, L. Martinii, and D. Quaglino. 1997. Altered lymphocyte antigen expression in HIV infection. Hematol. Pathol. 108:585–592.

10. Graziosi, C., G. Pantaleo, K. R. Gantt, J. P. Fortin, J. F. Demarest, O. J. Cohen, R. P. Sekaly, and A. S. Fauci. 1994. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248–252.

11. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual, p. 354. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

12. Henne, V., P. Frei, and P. Burghiser. 1997. Beta-2-microglobulin—a rapid and automated determination for a broad range of clinical applications. Anticancer Res. 17:2915–2918.

13. Krishnan, L., L. Guibert, A. Russell, T. Wegmann, T. Mosmann, and M. Belosevic. 1996. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen specific IFN-γ response and increased production of T helper 2 cytokines. J. Immunol. 156:644–652.

14. Krishnan, L., L. Guibert, T. Wegmann, M. Belosevic, and T. Mosmann. 1996. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-γ and TNF and reduced IL-10 production by placental cells. J. Immunol. 156:653–662.

15. Lee, C., K. Ghoshal, and K. D. Beaman. 1990. Cloning of a cDNA for a T cell produced molecule with a putative immune regulatory role. Mol. Immunol. 27:1137–1144.

16. Lin, H., T. Mosmann, L. Guibert, S. Tuntipoppat, and T. Wegmann. 1993. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J. Immunol. 151:4862–4873.

17. Liu, Z., W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi. 1997. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD8+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquired Immune Defic. Syndr. Hum. Retrovirology 16:83–92.

18. Liu, Z., E. L. Hultin, W. G. Cumberland, P. Hultin, I. Schmid, J. L. Matul, R. Detels, and J. V. Giorgi. 1996. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 26:1–7.

19. Maggi, E., M. G. Giudizi, R. Biagiotti, F. Annunziato, R. Manetti, M-P. Piccinni, P. Parronchi, S. Sampognaro, L. Giannarini, G. Zuccati, and S. Romagnani. 1994. Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J. Exp. Med. 180:489–495.

20. Mandal, M., and K. D. Beaman. 1995. Purification and characterization of a pregnancy-associated protein: Tj6a. Am. J. Reprod. Immunol. 35:60–67.

21. Martin, S. J., and D. R. Green. 1995. Apoptosis during HIV infection. A cytopathic effect of HIV or an important host-defense mechanism against viruses in general? Adv. Exp. Med. Biol. 374:129–138.

22. McCloskey, T. W., N. Oyaizu, M. Kaplan, and S. Pahwa. 1995. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry 22:111–114.

23. Muro-Cacho, C. A., G. Pantaleo, and A. S. Fauci. 1995. Analysis of apoptosis in lymph node cells of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J. Immunol. 154:5555–5566.

24. Nichols, T. C., J. A. Kang, V. Angkachatchai, A. E. Beer, and K. D. Beaman. 1994. Expression of a membrane form of the pregnancy-associated protein Tj6 on lymphocytes. Cell. Immunol. 155:219–229.

25. Patki, A. H., D. L. Georges, and M. M. Lederman. 1997. CD4+ T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects. Clin. Diagn. Lab. Immunol. 4:736–741.

26. Ribbing, S. L., R. C. Hoversland, and K. D. Beaman. 1988. T-cell suppressor factors play an integral role in preventing fetal rejection. J. Reprod. Immunol. 14:83–95.

27. Rizzardi, G. P., G. Tambussi, W. Barcellini, B. Capiluppi, E. Clerici, L. L. Maestra, F. Lillo, G. Pantaleo, and A. Lazzarin. 1997. Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: relationship with HIV-1 RNA, clinical outcome and early antiviral therapy. J. Biol. Regul. Homeost. Agents 1:43–49.

28. Rosenberg, Z. F., and A. S. Fauci. 1989. The immunopathogenesis of HIV infection. Adv. Immunol. 47:377–431.

29. Rubesa, G., K. D. Beaman, P. Lucin, A. E. Beer, and D. Rukavina. 1994. Expression of Tj6 protein in the human first trimester decidual lymphocytes. Reg. Immunol. 6:331–333.

30. Stein, D. S., R. H. Lyles, N. M. Graham, C. J. Tassoni, J. B. Margolick, J. P. Phair, C. Rinaldo, R. Detels, A. Saah, and J. Bilello. 1997. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. J. Infect. Dis. 176:1161–1167.

31. Sunilia, L. M. Vaccarezza, G. Pantaleo, A. S. Fauci, and J. M. Orenstein. 1997. gp120 is present on the plasma membrane of apoptotic CD4 cells prepared from lymph nodes of HIV-1-infected individuals: an immunoelectron microscopic study. AIDS 11:27–32.

32. Tezabwala, B., P. Johnson, and R. Rees. 1989. Inhibition of pregnancy viability in mice following IL-2 administration. Immunology 67:115–119.

33. Wegmann, T. G., H. Lin, L. Guibert, and T. R. Mosmann. 1993. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today 14:353–356.